Here we show that USP28 dysregulates NOTCH1 signaling in CLL and demonstrate that USP28 inhibition with the small molecule inhibitor AZ1 could be a new therapeutic option in CLL (Fig. 8). Here, NOTCH1 is linked to B-cell chronic lymphocytic leukemia.